Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo ® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell ...
On Monday, the FDA accepted the supplemental biologics license application (sBLA) for Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line ...
Bristol Myers Squibb has won Food and Drug Administration priority review for its application seeking approval of the combination of its Opdivo and Yervoy cancer drugs for the early treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback